Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Asset Writedowns and Impairment (2023 - 2025)

Senti Biosciences' quarterly Asset Writedowns and Impairment came in at $5.1 million in Q4 2025, up 1584.0% year-on-year from $300000.0 in Q4 2024, and up 1584.0% quarter-over-quarter from $300000.0 in Q4 2024.

Senti Biosciences has reported Asset Writedowns and Impairment for 3 years, with the latest figure at $5.1 million in Q4 2025.

  • For the quarter ending Q4 2025, Asset Writedowns and Impairment rose 1584.0% year-over-year to $5.1 million; the trailing twelve-month figure through Dec 2025 stood at $5.6 million (down 78.59% YoY), and the FY2025 full-year result was $5.1 million, up 1514.06% from the prior year.
  • Asset Writedowns and Impairment for Q4 2025 stood at $5.1 million, up from $300000.0 in the prior quarter.
  • The five-year high for Asset Writedowns and Impairment was $25.7 million in Q3 2023, with the low at $271000.0 in Q4 2023.
  • Average Asset Writedowns and Impairment over 3 years is $7.8 million, with a median of $2.7 million recorded in 2024.
  • Year-over-year, Asset Writedowns and Impairment grew 10.7% in 2024 and soared 1584.0% in 2025.
  • Tracing SNTI's Asset Writedowns and Impairment over 3 years: stood at $271000.0 in 2023, then climbed by 10.7% to $300000.0 in 2024, then soared by 1584.0% to $5.1 million in 2025.
  • The last three Asset Writedowns and Impairment figures came in at $5.1 million (Q4 2025), $300000.0 (Q4 2024), and $271000.0 (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Senti Biosciences Holdings 22.25 Mn 22.25 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 5.05 Mn
Dec 31, 2025 5.05 Mn
Dec 31, 2024 300,000.00
Dec 31, 2024 300,000.00
Dec 31, 2023 271,000.00
Dec 31, 2023 271,000.00
Sep 30, 2023 25.69 Mn
Sep 30, 2023 25.69 Mn